Company: NOTV
Filing Date: 2025-02-06
Form Type: 10-Q
Source: 0001628280-25-004178
Chunk: 107

Company: Inotiv, Inc.
Filing Date: 2025-02-06
Form: 10-Q
Item: Part II, Item 8
Chunk 107
---
3: Three Months EndedDecember 31, 20242023RevenueDSA:Service revenue$41,843 $43,563 Product revenue979 1,135 RMS:Service revenue11,714 10,300 Product revenue65,340 80,503 $119,876 $135,501 Operating Income (Loss)DSA$1,946 $1,593 RMS(1,185)5,078 Unallocated Corporate(16,268)(16,042)$(15,507)$(9,371)Interest expense(13,838)(11,364)Other (expense) income(463)1,413 Loss before income taxes$(29,808)$(19,322)

14

The following table presents depreciation and amortization and capital expenditures by reportable segment for the three months ended December 31, 2024 and 2023:Three Months EndedDecember 31,20242023Depreciation and amortization: DSA$4,583 $4,409 RMS9,438 9,737   Unallocated Corporate158 104  $14,179 $14,250  Capital expenditures:DSA$376 2,275 RMS4,083 3,297  $4,459 $5,572 Geographic InformationThe following represents revenue originating in entities physically located in the identified geographic area:Three Months EndedDecember 31,20242023United States$97,399 $111,769 Netherlands15,834 18,062 Other6,643 5,670 $119,876 $135,501 Long-lived assets shown below include property and equipment, net. The following represents long-lived assets where they are physically located:December 31,September 30,20242024United States$163,221 $167,772 Netherlands6,278 7,159 Other12,780 13,397 $182,279 $188,328 

15

4.    DEBT

Long-term debt as of December 31, 2024 and September 30, 2024 is detailed in the table below. December 31, 2024September 30, 2024Seller Note – Bolder BioPath (Related party)$320 $376 Seller Note – Preclinical Research Services— 464 Seller Payable - Orient BioResource Center3